Endometrial cancer – an update

Sanderson, Peter; Moulla, Alexandra; Fegan, Scott

doi:10.1016/j.ogrm.2019.05.001

Cited by 3 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conventionally, endometrial carcinomas have been classified as type I and type II; type I tumors were estrogen dependent and associated with endometrial hyperplasia, whereas type II tumors were estrogen independent and associated with endometrial atrophy. Endometrial carcinoma is also classified according to histopathological characteristics, with the most common subtypes being endometrioid carcinoma, serous carcinoma, carcinosarcoma, and clear cell carcinoma [5].…”

Section: Introductionmentioning

confidence: 99%

Immunohistochemical Expression of “L1 cell Adhesion Molecule” in Endometrial Carcinomas

Elyamany¹,

Abdelaziz²,

El-Sheikh³

et al. 2020

Open Access Maced J Med Sci

View full text Add to dashboard Cite

BACKGROUND: Endometrial cancer is the most common cancer of the female genital tract. No effective biomarkers currently exist to allow for an efficient risk classification of endometrial carcinoma or to direct treatment (adjuvant radiation and/or chemotherapy) or to triage pelvic and para-aortic lymphadenectomy. L1 cell adhesion molecule (L1CAM) a transmembrane protein of the immunoglobulin family that has been implicated in promoting tumor cell proliferation, migration, invasion, and metastasis became an attractive candidate as a potential biomarker in endometrial carcinoma and potential therapeutic target in high-risk groups. OBJECTIVES: Evaluation of L1CAM expression in endometrial carcinoma and correlation of this expression with various pathological parameters. MATERIALS AND METHODS: Immunohistochemical staining for L1CAM was performed on paraffin-embedded sections of 80 cases of endometrial carcinomas that underwent total hysterectomy with bilateral salpingo-oophorectomy. Expression of L1CAM in >10% of tumor cells was interpreted as positive. RESULTS: L1CAM expression was detected in 22.5% of cases and showed statistically significant correlation with non-endometrioid histological type, high grade, high FIGO stage, high pathological (T) stage, cervical involvement, nodal metastasis, lymphovascular space invasion, and high-risk tumor according to the European Society for Medical Oncology system for risk stratification (p < 0.05). CONCLUSION: The high rate of L1CAM expression in high-risk endometrial carcinomas suggests that L1CAM represents a potential marker for the identification of patients needing closer follow-up and aggressive treatment. In addition, its potential role as a therapeutic target for high-risk endometrial cancer seems promising.

show abstract

Section: Introductionmentioning

confidence: 99%

Immunohistochemical Expression of “L1 cell Adhesion Molecule” in Endometrial Carcinomas

Elyamany¹,

Abdelaziz²,

El-Sheikh³

et al. 2020

Open Access Maced J Med Sci

View full text Add to dashboard Cite

show abstract

“…Surgery, chemotherapy and radiotherapy are the main treatments for patients with EC [5,6]. The 2009 International Federation of Gynecology and Obstetrics (FIGO) and the tumor-node-metastasis classifications are the most commonly used classifications based on surgical staging [7].…”

mentioning

confidence: 99%

Clinicopathological study of organ metastasis in endometrial cancer

Mao¹,

Sang

Yang

et al. 2020

Future Oncol.

View full text Add to dashboard Cite

Aim: Our aim was to analyze the clinicopathological features of lung, liver, bone and brain metastasis in patients with endometrial cancer (EC). Patients & methods: We screened patients diagnosed with EC between 2010 and 2015 from the Surveillance, Epidemiology and End Results database. Results: Among 69,027 eligible EC patients, lung metastasis was the most common. Patients with lung or liver metastasis were at higher risk of bone and brain metastases than those without lung and liver metastasis. Brain metastasis has the lowest survival time (5.0 months) in single organ metastasis. Liver and brain metastasis have the highest death rate in two organ metastasis, and lung, liver and brain metastasis had the lowest survival time (1.0 month) in multi-sites metastasis. Conclusion: Lung metastasis was the most common in EC patients. Assessing distant organ metastasis may help clinicians to determine appropriate follow-up strategy for patients with EC.

show abstract

“…Endometrial cancer (EC) is the 4 th most frequently diagnosed gynaecological malignancy in the first world, and also the 4 th most common cancer to affect women in the UK (1,2). In 2018, >382,000 women were diagnosed with EC, and approximately 90,000 fatalities were recorded worldwide (3).…”

Section: Introductionmentioning

confidence: 99%